Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Merck
Medtronic
Harvard Business School

Last Updated: May 20, 2022

CANASA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Canasa, and when can generic versions of Canasa launch?

Canasa is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in thirteen countries.

The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Canasa

A generic version of CANASA was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.

  Sign up for a Free Trial

Drug patent expirations by year for CANASA
Drug Prices for CANASA

See drug prices for CANASA

Drug Sales Revenue Trends for CANASA

See drug sales revenues for CANASA

Recent Clinical Trials for CANASA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SandozPhase 3
Axcan PharmaPhase 3
Forest LaboratoriesPhase 3

See all CANASA clinical trials

Pharmacology for CANASA
Drug ClassAminosalicylate
Paragraph IV (Patent) Challenges for CANASA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CANASA Suppository mesalamine 1000 mg 021252 1 2013-05-24

US Patents and Regulatory Information for CANASA

CANASA is protected by two US patents.

Patents protecting CANASA

Mesalamine suppository
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Mesalamine suppository
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan CANASA mesalamine SUPPOSITORY;RECTAL 021252-002 Nov 5, 2004 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan CANASA mesalamine SUPPOSITORY;RECTAL 021252-002 Nov 5, 2004 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan CANASA mesalamine SUPPOSITORY;RECTAL 021252-001 Jan 5, 2001 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CANASA

See the table below for patents covering CANASA around the world.

Country Patent Number Title Estimated Expiration
Israel 220397 See Plans and Pricing
European Patent Office 2512443 SUPPOSITOIRE DE MÉSALAMINE (MESALAMINE SUPPOSITORY) See Plans and Pricing
European Patent Office 2512443 SUPPOSITOIRE DE MÉSALAMINE (MESALAMINE SUPPOSITORY) See Plans and Pricing
Mexico 2012006902 SUPOSITORIO DE MESALAMINA. (MESALAMINE SUPPOSITORY.) See Plans and Pricing
Chile 2012001636 Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa. See Plans and Pricing
Israel 220397 See Plans and Pricing
Japan 2013514979 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Express Scripts
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.